Who
Evert B. Schimmelpennink
Director
Company insider
Files Form 4 as: Director, Contineum Therapeutics; President, CEO and Secretary, LENZ Therapeutics; Director, iBio; Director and Officer, Pfenex.
In numbers
- Trades disclosed
- 37
- Buys
- 2
- Sells
- 0
- Bought
- $553K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Sep 2017
- Last trade
- 26 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 26 Jun 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 27 Mar 2026filed 30 Mar 2026 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $251K28,089 at $8.95 | filing |
| 27 Mar 2026filed 30 Mar 2026 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $251K28,089 at $8.95 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —358,100 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —358,100 at $0.00 | filing |
| 20 Nov 2025filed 24 Nov 2025 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 26 Jun 2025filed 26 Jun 2025 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,750 at $0.00 | filing |
| 7 Mar 2025filed 7 Mar 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,200 at $0.00 | filing |
| 7 Mar 2025filed 7 Mar 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code M | $4,3684,200 at $1.04 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —279,100 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,900 at $0.00 | filing |
| 22 Jul 2024filed 23 Jul 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,000 at $0.00 | filing |
| 22 Jul 2024filed 23 Jul 2024 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K45,000 at $1.04 | filing |
| 24 May 2024filed 29 May 2024 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —387,106 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,723 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —315,864 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,000 at $0.00 | filing |
| 9 Dec 2021filed 13 Dec 2021 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —109,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.